azlocillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 277 37091-66-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • azlocillin
  • azlocillin sodium
  • azlocillin sodium salt
A semisynthetic ampicillin-derived acylureido penicillin.
  • Molecular weight: 461.49
  • Formula: C20H23N5O6S
  • CLOGP: 1.56
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 4
  • TPSA: 148.15
  • ALOGS: -3.30
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
12 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 65 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 650.05 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.65 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.915 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.622 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.578 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.622 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 75.420 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 59.830 % High 1
herg hERG pIC50 4.380 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.023 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.090 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 72.910 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,STK33,SYK,TEK 22
kinase-selectivity-class AXL,BRAF,CDK9,GRK2,PDK1 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.791 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.222 High 1
mppb Mouse plasma protein binding (% unbound) 68.730 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.276 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 61.090 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.151 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.970 % High 1
rppb Rat plasma protein binding (% unbound) 56.980 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 931.108 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 3, 1982 FDA BAYER PHARMACEUTICALS CORP

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CA09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Penicillins with extended spectrum
CHEBI has role CHEBI:36047 antibacterial drug
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Related Drugs by ATC class:

J01CA Penicillins with extended spectrum 18 drugs
amoxicillinampicillinaspoxicillinbacampicillincarbenicillincarindacillinepicillinhetacillinmecillinammetampicillinmezlocillinpiperacillin show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Pneumonia due to Pseudomonas indication 41381004
Pneumonia due to Escherichia coli indication 51530003
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Bacterial infection due to Serratia indication 71120004
Infection of bone indication 111253001
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Infectious disorder of joint indication 363162000
Aspiration pneumonia indication 422588002 DOID:3240
Enterobacter Pneumonia indication
Cholangitis off-label use 82403002 DOID:9446
Infectious disease of abdomen off-label use 128070006
Abscess of brain off-label use 441806004
Pseudomonas Aeruginosa Meningitis off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 12.4 acidic
pKa3 12.92 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4019621 VUID
N0000147715 NUI
D02339 KEGG_DRUG
1266 RXNORM
C0004499 UMLSCUI
CHEBI:2956 CHEBI
CHEMBL1537 ChEMBL_ID
CHEMBL1201041 ChEMBL_ID
D001390 MESH_DESCRIPTOR_UI
DB01061 DRUGBANK_ID
12260 IUPHAR_LIGAND_ID
4011 INN_ID
37091-65-9 SECONDARY_CAS_RN
HUM6H389W0 UNII
6479523 PUBCHEM_CID
4018389 VANDF
4019621 VANDF
002697 NDDF
004836 NDDF
10730008 SNOMEDCT_US
387308000 SNOMEDCT_US
55432002 SNOMEDCT_US

Pharmaceutical products:

None